Project Grant R01NS139479
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$687K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to improve immunogene therapy for the treatment of glioblastoma, a highly fatal type of brain cancer. The $633,656 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will support preclinical research to investigate...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will support exploratory studies on the role of TREM1 and TREM2 receptors in modulating the immune response to glioblastoma (GBM), a highly aggressive and difficult-to-treat form of brain cancer. The $472,124 award, granted to Beth Israel Deaconess Medical Center (Bidmc), will...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $449,203 to support research aimed at investigating the interaction between glioblastoma (GBM), the most aggressive form of brain cancer, and the subventricular zone (SVZ) neurogenic niche in the lateral ventricles. The research, led by Mayo Clinic Jacksonville, a nonprofit...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $420,251 to Brigham & Women's Hospital Inc. to develop encapsulated cell-based oncolytic virus therapy for brain tumors. The project aims to enhance the therapeutic efficacy of engineered mesenchymal stem cells (MSCs) armed with oncolytic herpes simplex virus (OHSV)...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $574,427 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Pittsburgh to investigate the role of amino acid metabolism in regulating the growth and immune interactions of glioblastoma, an aggressive form of brain cancer. The research aims to uncover the molecular and cellular mechanisms by which selective amino acid catabolism in glioblastoma...
This federal Project Grant award of $649,226 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, supports research to investigate mechanisms of therapeutic resistance and mesenchymal transition in glioblastoma (GBM) brain tumors. The research aims to dissect and target the acetylated RelA (NF-κB subunit):BET protein complex, which acts as a regulatory switch...
This $460,940 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to investigate the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories. The research focuses on elucidating the epigenetic and transcriptional mechanisms by which two specific glioma-associated risk SNPs, rs7572263 and rs78378222, dysregulate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), provides USD 627,061 to develop innovative oncolytic immunotherapies for the treatment of glioblastoma (GBM), a fatal form of brain cancer. The key objectives are to: Determine if combining MGH's genetically-engineered oncolytic herpes simplex virus (oHSV) expressing IL-12 with inhibitors of...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $230,580 to Brigham & Women's Hospital Inc. to conduct research focused on understanding the mechanisms underlying brain-immune interactions at the blood-brain barrier. The overarching goal is to generate novel targets for immunotherapy in neuroinflammatory...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,064,642 in funding to Tufts Medical Center to study the role of angiogenin (ANG) and plexin-B2 (PLXNB2) in maintaining the stemness properties of glioblastoma stem cells (GSCs) and preventing glioblastoma (GBM) recurrence. The research aims to characterize the ANG-PLXNB2-tRNA-derived stress-induced small RNA (tiRNA) axis as a regulatory pathway that sustains GSC properties, and...